Cognition Therapeutics CMO buys 10,000 shares
Cognition Therapeutics Inc. Chief Medical Officer Anthony Caggiano reported an open-market purchase of 10,000 shares of the company’s Common Stock on April 16, 2026 at a price of $1.11 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cognition Therapeutics Inc. Chief Medical Officer Anthony Caggiano reported an open-market purchase of 10,000 shares of the company’s Common Stock on April 16, 2026 at a price of $1.11 per share. Following this transaction, his direct holdings increased to 874,906 shares of Common Stock.
Insider Trade Summary
Net Buyer: 10,000 shares
Net Buy
1 txn
Insider
Caggiano Anthony
Role
Chief Medical Officer
Bought
10,000 shs ($11K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 10,000 | $1.11 | $11K |
Holdings After Transaction:
Common Stock — 874,906 shares (Direct)
Key Figures
Shares purchased: 10,000 shares
Purchase price: $1.11 per share
Shares held after transaction: 874,906 shares
+1 more
4 metrics
Shares purchased
10,000 shares
Open-market purchase on April 16, 2026
Purchase price
$1.11 per share
Price paid for Cognition Therapeutics Common Stock
Shares held after transaction
874,906 shares
Direct Common Stock holdings after April 16, 2026 trade
Net buy shares
10,000 shares
Net effect of reported Form 4 transactions
Key Terms
open-market purchase, Common Stock, Form 4, Chief Medical Officer
4 terms
open-market purchase financial
"reported an open-market purchase of 10,000 shares of the company’s Common Stock"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Common Stock financial
"10,000 shares of the company’s Common Stock on April 16, 2026"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"according to a new Form 4 filing"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Chief Medical Officer financial
"Chief Medical Officer Anthony Caggiano reported an open-market purchase"
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cognition Therapeutics (CGTX) report on this Form 4?
The filing shows Chief Medical Officer Anthony Caggiano completed an open-market purchase of 10,000 shares of Cognition Therapeutics Common Stock at $1.11 per share, increasing his direct ownership stake in the company.
Who is the Cognition Therapeutics (CGTX) insider involved in this Form 4?
The insider is Anthony Caggiano, the Chief Medical Officer of Cognition Therapeutics. He reported buying 10,000 shares of Common Stock in an open-market transaction, bringing his directly held position to 874,906 shares after the purchase.
What are Anthony Caggiano’s Cognition Therapeutics (CGTX) holdings after this Form 4 transaction?
After the reported transaction, Anthony Caggiano directly holds 874,906 shares of Cognition Therapeutics Common Stock. This total reflects his position immediately following the open-market purchase of 10,000 additional shares disclosed in the Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates